CGON CG Oncology, Inc.
CG Oncology, Inc. (CGON) is expected to report earnings on November 5, 2026, before the market open. The consensus earnings estimate is a loss of $0.86 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +4.4% since its last earnings release on August 6, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About CG Oncology, Inc.
CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. CG Oncology is based in IRVINE, Calif.
Sector
Healthcare
Industry
Biotechnology